Anal Cancer – Pipeline Review, H1 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Anal
Cancer – Pipeline Review, H1 2019”
drug pipelines has been
added to ResearchAndMarkets.com’s offering.

Anal Cancer – Pipeline Review, H1 2019 provides
comprehensive information on the therapeutics under development for Anal
Cancer (Oncology), complete with analysis by stage of development, drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type.

The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases. The Anal Cancer (Oncology) pipeline guide also
reviews of key players involved in therapeutic development for Anal
Cancer and features dormant and discontinued projects.

The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Phase II, Phase I and Preclinical stages are 16, 10 and 5
respectively.

Anal Cancer (Oncology) pipeline guide helps in identifying and tracking
emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to
gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic
    landscape of Anal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Anal Cancer
    (Oncology) by companies and universities/research institutes based on
    information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of
    development ranging from pre-registration till discovery and
    undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline
    products which comprise, product description, descriptive licensing
    and collaboration details, R&D brief, MoA & other developmental
    activities.
  • The pipeline guide reviews key companies involved in Anal Cancer
    (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anal Cancer (Oncology) therapeutics based
    on mechanism of action (MoA), drug target, route of administration
    (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued
    pipeline projects.
  • The pipeline guide reviews latest news related to pipeline
    therapeutics for Anal Cancer (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and
    insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio
    and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under
    development for Anal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of
    leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players
    and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding
    Anal Cancer (Oncology) pipeline depth and focus of Indication
    therapeutics.
  • Develop and design in-licensing and out-licensing strategies by
    identifying prospective partners with the most attractive projects to
    enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects
    and understand from the know-how what drove them from pipeline.

Key Topics Covered

1. Introduction

2. Anal Cancer – Overview

3. Anal Cancer – Therapeutics Development

4. Anal Cancer – Therapeutics Assessment

5. Anal Cancer – Companies Involved in Therapeutics Development

6. Anal Cancer – Drug Profiles

7. Anal Cancer – Dormant Projects

8. Anal Cancer – Discontinued Products

9. Anal Cancer – Product Development Milestones

10. Appendix

Companies Mentioned

  • Antiva Biosciences Inc.
  • Bayer AG
  • BeiGene Ltd.
  • Bristol-Myers Squibb Co.
  • Cleveland BioLabs Inc.
  • Cue Biopharma Inc.
  • CytomX Therapeutics Inc.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corp.
  • Genentech Inc.
  • IMV Inc.
  • Incyte Corp.
  • ISA Pharmaceuticals B.V.
  • Kite Pharma Inc.
  • MedImmune LLC
  • Merck & Co. Inc.
  • Merck KGaA
  • OncoMed Pharmaceuticals Inc.
  • Onconova Therapeutics Inc.
  • Ono Pharmaceutical Co. Ltd.
  • PDS Biotechnology Corp.
  • Sierra Oncology Inc.
  • THEVAX Genetics Vaccine USA Inc.
  • Transgene S.A.
  • Virion Therapeutics LLC

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ff85m8

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs
, Colon
Cancer Drugs